Intriguingly, stachydrine could effectively inhibit LPS-induced inflammatory bone loss by suppressing NF-κB and Akt signal pathway (Meng et al., 2019), suggesting its future use in the treatment of postpartum osteoporosis. This evidence concerns the gene AKT1 and osteoporosis.